GIM
BLFS icon

Glenmede Investment Management’s BioLife Solutions BLFS Stock Holding History

Glenmede Investment Management’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$327K Buy
12,826
+279
+2% +$6.62K ﹤0.01% 1089
2025
Q2 		$270K Buy
+12,547
New +$283K ﹤0.01% 1142

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Glenmede Investment Management's BLFS Position: Q3 2025 in Review

Glenmede Investment Management increased its BioLife Solutions (BLFS) stake by 2.2% in Q3 2025, buying an estimated $6.62K and bringing the position to 12,826 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #1089.

Glenmede Investment Management first reported a position in BLFS in Q2 2025 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold BLFS as of Q3 2025.

  • Glenmede Investment Management held 12,826 shares of BioLife Solutions worth $327K as of Q3 2025.
  • Glenmede Investment Management bought 279 BioLife Solutions shares in Q3 2025, an estimated $6.62K.
  • BioLife Solutions made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1089 holding.
  • Glenmede Investment Management first reported a position in BioLife Solutions in Q2 2025 and has held it in 2 quarters since.
  • 192 funds tracked by Wall St. Rank held BioLife Solutions as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.